A dose of Pfizer-Bioentech vaccine may be sufficient to give a strong immune response after 11 days. According to other researchers, including Heidi E. Drummer of Monash University in Australia, the second ‘booster’ dose of the vaccine may not increase the efficacy of the vaccine against SARS-COV-2.
The team re-examined the Pfizer-BioNotech Phase 3 trial data from the first day to the 111th day in the placebo and experimental group for the study.
He also looked at Moderna’s vaccine trial data. Although the number of Kovid-19 cases in the Moderna trial was low in the first few weeks, they did not have enough data to assess it. Instead, Moderna’s trial data were used for comparison purposes with Pfizer’s trial data.
He studied the efficacy of the vaccine from day 11 to day 28 and compared it to day 111 of the second dose of vaccine given on the second day. According to reports, the dose of the first vaccine indicated that giving the second dose helped develop the antibody.